Related Experiment Video
Updated: May 22, 2025
12:52
Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells
Published on: November 28, 2015
15.7K
Immune Cell Interplay in the Fight Against GBM
Nico Vallieri1, Angeliki Datsi1
1Institute for Transplantation Diagnostics and Cell Therapeutics, Medical Faculty and University Hospital Duesseldorf, Heinrich-Heine-University Düsseldorf, 40225 Duesseldorf, Germany.
Cancers
|March 13, 2025
Summary
Glioblastoma (GBM) is hard to treat due to complex cancer cell behaviors and resistance to therapies. New treatments like targeted therapies and immunotherapies show promise for overcoming these challenges.
Area of Science:
- Neuro-oncology
- Cancer Biology
- Immunology
Background:
- Glioblastoma (GBM) presents significant therapeutic challenges due to its complex biology, including invasive phenotypes, chemo-resistance, and immune evasion.
- Advanced GBM tumors create hypoxic, immunosuppressive microenvironments, fostering proliferation and survival through angiogenesis.
- Hallmarks of GBM include immunosuppressive cells, immune checkpoint molecule expression, and low neoantigen burden, hindering effective treatment.
Purpose of the Study:
- To review the multifaceted mechanisms employed by GBM to sustain tumor growth.
- To explore emerging therapeutic strategies targeting GBM's unique biological characteristics.
- To highlight advancements in both conventional and novel treatment modalities for glioblastoma.
Main Methods:
- Review of current literature on glioblastoma pathogenesis and treatment resistance.
- Analysis of mechanisms driving tumor growth, invasion, and immune evasion in GBM.
- Evaluation of preclinical and clinical data for novel therapeutic agents and immunotherapies.
Main Results:
- GBM utilizes specialized phenotypes, hypoxia, angiogenesis, and an immunosuppressive microenvironment to promote growth and evade the immune system.
- Resistance to conventional therapies is a major hurdle, necessitating innovative treatment approaches.
- Emerging therapies include novel chemotherapeutics, tumor treating fields, targeted small molecules, and advanced immunotherapies.
Conclusions:
- Targeting GBM requires a comprehensive strategy addressing tumor cell proliferation, invasion, angiogenesis, and immune suppression.
- Immunotherapies, including immune checkpoint blockade, dendritic cell vaccination, and CAR-T cell therapy, offer promising avenues for overcoming GBM's immune escape mechanisms.
- Combination therapies integrating conventional treatments with novel agents and immunotherapies may represent the most effective path forward for glioblastoma treatment.
